Human Recombinant IFN-beta, STEMCELL Technologies (CAT#: STEM-CT-0885-ZJF)

Interferon beta (IFN-β), also known as type I interferon, is produced by fibroblasts, and in smaller amounts by plasmocytoid dendritic cells. Macrophages and endothelial cells secrete IFN-β in response to a viral infection (Reder & Feng). IFN-β binds to a receptor complex composed of IFNAR1 and IFNAR2, and initiates signal transduction via the JAK/STAT pathway; this culminates in the transcription and activation of many genes that control dendritic cell activation, T cell survival, NK cell activation, chemokine expression, lymph node retention, and antiproliferative and antiviral effects (Dunn et al.). IFN-β is a first-line treatment for multiple sclerosis. It suppresses Th17 cells by affecting expression of IL-4, IL-10, and IL-27. IFN-β was also shown to expand regulatory T cells and limit T cell trafficking to the central nervous system (Inoue & Shinohara). Out of the two variants of IFN-β (IFN-β1 and IFN-β3), this product is the IFN-β1 form.

Subtype: Cytokines
Cell Type: B Cells, Cancer Cells and Cell Lines, NK Cells, T Cells
Species: Human
Area of Interest: Cancer, Immunology
Purity: ≥ 95%

Reliable Consistency: Guarantees uniformity and repeatability in various applications with endotoxin levels below 0.2 EU/μg.
Free of Animal Components: Completely devoid of any animal or human-derived elements.
Broad Selection: Offers a wide range of human, mouse, and rat cytokines available in multiple sizes.

Human Recombinant IFN-alpha 2A, STEMCELL Technologies
Human Recombinant IFN-alpha 2B, STEMCELL Technologies
Human Recombinant IFN-gamma, STEMCELL Technologies
Human Recombinant IFN-gamma, ACF, STEMCELL Technologies